Wayne J. Fairbrother

18.0k total citations · 2 hit papers
122 papers, 9.1k citations indexed

About

Wayne J. Fairbrother is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Wayne J. Fairbrother has authored 122 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Molecular Biology, 28 papers in Oncology and 24 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Wayne J. Fairbrother's work include Cell death mechanisms and regulation (33 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Ubiquitin and proteasome pathways (15 papers). Wayne J. Fairbrother is often cited by papers focused on Cell death mechanisms and regulation (33 papers), Monoclonal and Polyclonal Antibodies Research (21 papers) and Ubiquitin and proteasome pathways (15 papers). Wayne J. Fairbrother collaborates with scholars based in United States, France and United Kingdom. Wayne J. Fairbrother's co-authors include Domagoj Vucic, Kurt Deshayes, Vishva M. Dixit, Andrew J. Souers, Melissa A. Starovasnik, Anna Fedorova, Joel Johansson, Kerry Zobel, Eugene Varfolomeev and Avi Ashkenazi and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Wayne J. Fairbrother

121 papers receiving 8.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis

2007 1.0k citations Eugene Varfolomeev, Jasmin N. Dynek et al. profile →
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

2017 667 citations Wayne J. Fairbrother, Joel Johansson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wayne J. Fairbrother United States	51	6.7k	2.4k	1.9k	1.3k	729	122	9.1k
Kevin H. Mayo United States	55	6.0k 0.9×	3.1k 1.3×	1.7k 0.9×	663 0.5×	526 0.7×	283	10.5k
Christian Wiesmann United States	47	5.6k 0.8×	2.4k 1.0×	1.4k 0.7×	1.2k 1.0×	1.6k 2.2×	67	8.8k
Jarrod A. Marto United States	62	7.9k 1.2×	1.4k 0.6×	2.0k 1.0×	909 0.7×	346 0.5×	172	11.3k
Mark Ultsch United States	37	4.9k 0.7×	2.1k 0.9×	1.6k 0.8×	1.0k 0.8×	2.0k 2.8×	62	8.7k
Kazuyasu Sakaguchi Japan	50	8.8k 1.3×	4.2k 1.7×	5.5k 2.8×	1.5k 1.2×	836 1.1×	145	13.2k
Blagoy Blagoev Denmark	42	10.6k 1.6×	1.5k 0.6×	1.6k 0.8×	1.1k 0.9×	471 0.6×	108	14.1k
Keiryn L. Bennett Austria	45	5.8k 0.9×	2.2k 0.9×	1.1k 0.6×	525 0.4×	544 0.7×	120	9.5k
Abraham M. de Vos United States	48	6.8k 1.0×	1.9k 0.8×	2.6k 1.3×	1.2k 0.9×	2.2k 3.0×	65	10.9k
Scott B. Ficarro United States	56	7.8k 1.2×	922 0.4×	1.7k 0.9×	732 0.6×	537 0.7×	117	10.3k
Peter E. Czabotar Australia	47	8.9k 1.3×	2.2k 0.9×	2.1k 1.1×	926 0.7×	228 0.3×	98	11.8k

Countries citing papers authored by Wayne J. Fairbrother

Since Specialization

Citations

This map shows the geographic impact of Wayne J. Fairbrother's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wayne J. Fairbrother with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wayne J. Fairbrother more than expected).

Fields of papers citing papers by Wayne J. Fairbrother

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wayne J. Fairbrother. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wayne J. Fairbrother. The network helps show where Wayne J. Fairbrother may publish in the future.

Co-authorship network of co-authors of Wayne J. Fairbrother

This figure shows the co-authorship network connecting the top 25 collaborators of Wayne J. Fairbrother. A scholar is included among the top collaborators of Wayne J. Fairbrother based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wayne J. Fairbrother. Wayne J. Fairbrother is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alicke, Bruno, Eugene Varfolomeev, Alexandra Frommlet, et al.. (2022). IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition. Cell Death and Disease. 13(9). 831–831. 3 indexed citations

Adaligil, Emel, Aimin Song, Christian N. Cunningham, & Wayne J. Fairbrother. (2021). Ribosomal Synthesis of Macrocyclic Peptides with Linear γ⁴- and β-Hydroxy-γ⁴-amino Acids. ACS Chemical Biology. 16(8). 1325–1331. 16 indexed citations

Adaligil, Emel, Aimin Song, Kenneth K. Hallenbeck, Christian N. Cunningham, & Wayne J. Fairbrother. (2021). Ribosomal Synthesis of Macrocyclic Peptides with β²- and β^2,3-Homo-Amino Acids for the Development of Natural Product-Like Combinatorial Libraries. ACS Chemical Biology. 16(6). 1011–1018. 17 indexed citations

Punnoose, Elizabeth A., Joel Johansson, Franklin Peale, et al.. (2016). Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics. 15(5). 1132–1144. 223 indexed citations

Phillips, Aaron H., Allyn J. Schoeffler, Tsutomu Matsui, et al.. (2014). Internal Motions Prime cIAP1 for Rapid Activation. Biophysical Journal. 106(2). 253a–253a. 1 indexed citations

Tan, Nguyen, Michelle Nannini, Rebecca Hong, et al.. (2013). Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models. Molecular Cancer Therapeutics. 12(6). 853–864. 61 indexed citations

Sampath, Deepak, Sylvia Herter, Frank Herting, et al.. (2013). Combination of the glycoengineered Type II CD20 antibody obinutuzumab (GA101) and The novel Bcl-2 selective Inhibitor GDC-0199 Results in superior In Vitro and In Vivo Anti-tumor activity in models Of B-Cell Malignancies. Blood. 122(21). 4412–4412. 4 indexed citations

Tan, Nguyen, Jiping Zha, Franklin Peale, et al.. (2012). Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models. Molecular Cancer Therapeutics. 11(4). 1026–1035. 89 indexed citations

Tan, Nguyen, Jiping Zha, Yue Peng, et al.. (2011). Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models. Clinical Cancer Research. 17(6). 1394–1404. 83 indexed citations

10.

Dynek, Jasmin N., Sara M. Chan, Jinfeng Liu, et al.. (2008). Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas. Cancer Research. 68(9). 3124–3132. 82 indexed citations

11.

Kadkhodayan, Saloumeh, Linda O. Elliott, Heidi Ackerly Wallweber, et al.. (2007). Evaluation of Assay Technologies for the Identification of Protein–Peptide Interaction Antagonists. Assay and Drug Development Technologies. 5(4). 501–514. 13 indexed citations

12.

Jin, Hongkui, Renhui Yang, Calvin Ho, et al.. (2007). IAP (inhibitor of apoptosis) antagonist inhibits orthotopic lung tumor growth. Molecular Cancer Therapeutics. 6. 1 indexed citations

13.

Fairbrother, Wayne J.. (2007). Structure-based Design of IAP Antagonists. Molecular Cancer Therapeutics. 6. 1 indexed citations

14.

Franklin, Matthew C., Saloumeh Kadkhodayan, Daniela Alexandru, et al.. (2003). Structure and Function Analysis of Peptide Antagonists of Melanoma Inhibitor of Apoptosis (ML-IAP). Biochemistry. 42(27). 8223–8231. 74 indexed citations

15.

Jones, Jennifer T., Marcus Ballinger, Paul I. Pisacane, et al.. (1998). Binding Interaction of the Heregulinβ egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis. Journal of Biological Chemistry. 273(19). 11667–11674. 51 indexed citations

16.

Lowman, Henry B., et al.. (1996). Exchanging Interleukin-8 and Melanoma Growth-stimulating Activity Receptor Binding Specificities. Journal of Biological Chemistry. 271(24). 14344–14352. 70 indexed citations

17.

Jacobsen, Neil E., et al.. (1996). Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydrate Research. 280(1). 1–14. 96 indexed citations

18.

Stone, Martin J., Wayne J. Fairbrother, Arthur G. Palmer, et al.. (1992). Backbone dynamics of the Bacillus subtilis glucose permease IIA domain determined from nitrogen-15 NMR relaxation measurements. Biochemistry. 31(18). 4394–4406. 177 indexed citations

19.

Fairbrother, Wayne J., John Cavanagh, H. Jane Dyson, et al.. (1991). Polypeptide backbone resonance assignments and secondary structure of Bacillus subtilis enzyme IIIglc determined by two-dimensional and three-dimensional heteronuclear NMR spectroscopy. Biochemistry. 30(28). 6896–6907. 41 indexed citations

20.

Fairbrother, Wayne J., P.A. Walker, Philippe Minard, et al.. (1989). NMR analysis of site‐specific mutants of yeast phosphoglycerate kinase. European Journal of Biochemistry. 183(1). 57–67. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact